This article is more than 5 years old. Information may no longer be current.

FDA grants fast track designation to potential uveitis drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JERSEY CITY, N.J. — The U.S. Food and Drug Administration has granted fast track designation to Lux Biosciences for LX211, a calcineurin inhibitor being developed as a treatment for both noninfectious posterior and intermediate uveitis and for panuveitis, the company announced in a press release.

The FDA granted LX211 fast track designation because it "is intended for the treatment of a serious or life-threatening condition" and because it "demonstrates the potential to address medical needs unmet by available treatments," the release said.

Lux Biosciences is currently conducting three controlled, double-masked studies intended to support approval of LX211 for treating uveitis. Fast track designation will allow the company to expedite development and review of the drug, the release said.